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ENHANCED IMMUNE RECONSTITUTION BY INTERLEUKIN-7 (IL-7)
ADMINISTRATION AFTER ALLOGENEIC BONE MARROW TRANSPLAN-
TATION IN MURINE MODELS
Alpdogan, O.; Schmaltz, C.; Muriglan, S.J.; Kappel, B.J.; Rotolo, J.;
van den Brink, M. Memorial Sloan-Kettering Institute, New York, NY
Prolonged immunodeficiency after allogeneic bone marrow
transplantation (allo BMT) results in significant morbidity and
mortality from infection. Previous studies in murine syngeneic
BMT models have demonstrated that post-transplant IL-7 admin-
istration could enhance immune reconstitution. However, IL-7
administration after allo BMT was not tested and was thought to
potentially aggravate GVHD. We used murine models for MHC-
matched and -mismatched allo BMT with 3-month or 9-month
old recipients and administered 1-10 microg/day of human IL-7 at
various intervals after BMT. On day +28 all recipients (3-month
and 9-month old) had signiﬁcantly increased numbers of donor-
derived thymocytes, splenic CD4 and CD8 T cells and peripheral
blood lymphocytes. Further analysis of thymic precursors demon-
strated that double positive thymocytes and early thymic precur-
sors (DN1 and DN3) were signiﬁcantly increased as well. Mature,
pre-B and pro-B cell numbers were increased in the bone marrow
and spleen. In the spleen, all populations of CD4+ T cell (naïve,
activated and memory) and CD8 memory cells were increased.
Moreover, the T cell Vβ repertoire was not altered by IL-7 com-
pared to normal host animals.
Interestingly, IL-7 administration post BMT had no effect on
GVHD morbidity and mortality in MHC-matched recipients of
allo BM + splenic T cells. MHC-mismatched recipients (parent
into F1 model) had signiﬁcantly less GVHD morbidity and mor-
tality, whereas graft-versus-leukemia (GVL) activity (against
32Dp210 leukemia) remained intact. The decrease of GVHD was
associated with lower day +7 serum TNF levels as well as
decreased anti-host allo-reactivity.
In conclusion, post-transplant IL-7 administration can enhance
T and B cell reconstitution after allogeneic BMT without aggra-
vating GVHD or diminishing GVL activity.
MONITORING THE “CYTOKINE STORM” ASPECT OF ACUTE GVHD BY
MONOCYTE I.C. FLOW CYTOMETRY: POSITIVE CORRELATION WITH
GVHD ONSET, SEVERITY, AND RESPONSE TO THERAPY
Foley, J.E.; Leitzau, J.; Castro, K.; Kasten-Sportes, C.; Bishop, M.R.;
Fowler, D.H. National Cancer Institute, Bethesda, MD
Because peripheral blood monocytes are a source of IL-1 α and
TNF α that characterize the “cytokine storm” aspect of acute
GVHD, we hypothesized that monitoring of monocyte intracellu-
lar (i.c.) cytokine production by ﬂow cytometry would be a valu-
able method for evaluating acute GVHD. Monocyte i.c. ﬂow was
performed every 1 to 2 weeks after HLA-matched sibling allo-
geneic SCT using a non-myeloablative regimen that resulted in
rapid and complete donor chimerism. Acute GVHD was observed
in 10/10 evaluable patients by day 100 post-SCT using single
agent CSA prophylaxis (GVHD grade I, n=3; grade II, n=3, and
grade III, n=4); mean time to GVHD onset was 32 days (11-66 d).
In 10/10 cases, monocytes tested prior to day 10 post-SCT
expressed very low i.c. IL-1 and TNF (< 1% of cells positive).
However, in 10/10 cases, increased monocyte cytokine production
was detected prior to or at GVHD onset: six patients primarily
had elevated monocyte IL-1 alone (mean of 47.6% IL-1+, 1.7%
TNF+), whereas four patients had elevated IL-1 and TNF (mean
of 40.5% IL-1+, 17.5% TNF+). 4/4 patients with the IL-
1+/TNF+ profile developed gut GVHD (stages 1, 2, 3, 3); in
marked contrast, only 1/6 patients with the IL-1+/TNF- proﬁle
developed gut GHVD (stage 1). Six patients received IV steroids
for GVHD treatment: a rapid reduction in TNF+ monocytes was
observed in each case (3/3), whereas a reduction in monocyte IL-1
production was observed in only 1 of 6 steroid recipients. In con-
trast to these ﬁndings using i.c. ﬂow, serial monitoring of serum
levels of IL-1 and TNF by either two-site or competitive ELISA
did not correlate with GVHD clinical course. We conclude that
monocyte i.c. ﬂow cytometry for inﬂammatory cytokines is a new
method for characterizing cytokine events associated with clinical
GVHD onset, GVHD severity, and response to GVHD therapy.
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TRANSPLANTED GENE-MARKED MARROW MESENCHYMAL CELLS
ENGRAFT AND BENEFIT CHILDREN WITH SEVERE OSTEOGENESIS
IMPERFECTA: A PILOT TRIAL FOR MARROW CELL THERAPY OF MES-
ENCHYMAL DISORDERS
Horwitz, E.M.1; Gordon, P.L.1; Koo, W.K.2; Neel, M.D.1; Brown,
P.S.1; Marx, J.C.1; Hofmann, T.J.1 1. St. Jude Children’s Research
Hospital, Memphis, TN; 2. Wayne State University, Detroit, MI
Bone marrow stromal cells (MSCs) are mesenchymal progenitor
cells that have been shown to differentiate to multiple mesenchy-
mal tissues. Previously, we have shown that, in the context of allo-
geneic bone marrow transplantation (BMT), human marrow mes-
enchymal cells can engraft in bone and benefit children with
severe osteogenesis imperfecta (OI), a genetic disorder of
osteoblasts. In principle, then, allogeneic BMT has the potential
to attenuate disorders of bone, cartilage, and muscle. Here, we
describe initial results of a clinical trial of allogeneic MSC infu-
sions employing a double gene marking strategy to evaluate their
biologic and therapeutic potential. Patients with severe OI who
have previously undergone an allogeneic BMT were intravenously
infused with MSCs isolated from freshly harvested bone marrow
from the original donor. The MSCs were divided into two frac-
tions, each of which was transduced with a distinguishable retrovi-
ral vector. One fraction was briefly maintained in culture and
infused at a dose of 106 cells/kg, while the other was expanded
over three passages (500-1000 fold expansion) and infused at 5 x
106 cells/kg. To date, four patients have received MSC infusions.
DNA was isolated from cultured osteoblasts, skin ﬁbroblasts, and
marrow stromal cells and analyzed for the presence of the marking
genes by PCR. Engraftment of both minimally cultured cells and
expanded cells was demonstrated in bone, marrow stroma, and
skin. Six months after the infusions, patients increased their
growth velocity from a median of 10% (range 0-30%) to a median
of 69% (range 60-94%) of the predicted growth rates for age- and
sex-matched healthy children. There was no change in total body
bone mineral content 3 months after the infusions. Our results
suggest that allogeneic human MSCs can be isolated, expanded,
and retrovirally transduced while retaining their osteoprogenitor
potential, and safely infused into patients after BMT.
CO-ADMINISTRATION OF DONOR LYMPHOCYTE INFUSIONS (DLI) AND
TUMOR VACCINES LEADS TO POTENT GVT EFFECT AGAINST
METASTATIC BREAST AND COLON CANCER AND INDUCES ANTIGEN-
SPECIFIC T CELLS
Luznik, L.; Jill, S.E.; Ivan, B.; Hyam, L.; Drew, P.M.; Ephraim, F.J.
Johns Hopkins Oncology Center, Baltimore, MD
Numerous pre-clinical models show that irradiated, GM-CSF
secreting solid tumor cells can induce protection of syngeneic
mice from challenge with wild-type, unirradiated tumor. We
therefore hypothesized that allogeneic T cells, freshly infused
after alloBMT, could also be vaccinated to induce a potent and
specific GVT effect against a metastatic solid tumor. The first
model employed the 4T-1 breast cancer, of BALB/c (H-2d) ori-
gin, which produces widespread metastases within 14 days and
death within 30-40 days after subcutaneous inoculation. MHC-
compatible B10.D2 spleen cells, given as DLI after nonmyeloabla-
tive BMT, prevented the development of metastases but failed to
control subcutaneous tumor, and survival was minimally pro-
longed. To improve local and distant tumor control, subcutaneous
tumor was removed surgically prior to nonmyeloablative BMT,
and a tumor vaccine, consisting of irradiated tumor cells plus a
GM-CSF secreting bystander cell line, was administered at the
time of DLI. The combination of surgery of local tumor with
active and adoptive immunotherapy of metastases resulted in cure
of 18 of 20 animals. Long-term cured animals were healthy, mixed
hematopoietic chimeras, exhibited CTL tolerance of both donor
and host histocompatibility antigens, and four of five animals
resisted intravenous re-challenge with the original tumor. In a sec-
ond set of experiments, ten of ten B10.D2→BALB/c mixed
chimeras were protected from challenge with CT-26 colon can-
cer, of BALB/c origin, by co-administration of B10.D2 DLI plus a
CT-26/GM-CSF bystander vaccine, compared to 0/10 mixed
chimeras protected by DLI alone. In addition, protected animals
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contained T cells speciﬁc for AH-1 (detected by ﬂow-cytometry
using MHC-Ig dimers), the immunodominant, MHC Class I-
binding, tumor-specific antigen expressed by CT-26. Taken
together, the results demonstrate that allogeneic T cells can be
vaccinated after nonmyeloablative BMT to generate a potent,
tumor-speciﬁc response capable of curing metastatic solid tumors.
BONE MARROW TRANSPLANTATION (BMT) FOR SICKLE CELL DISEASE
(SCD): UPDATED RESULTS OF A MULTICENTER INVESTIGATION
Walters, M.C.1; Patience, M.1; Leisenring, W.2; Storb, R.2; Sullivan,
K.M.3 1. Children’s Hospital Oakland, Oakland, CA; 2. Fred Hutchin-
son Cancer Research Center, Seattle, WA; 3. Duke Univ. Medical Cen-
ter, Durham, NC
A multicenter investigation of allogeneic marrow transplanta-
tion for children with SCD was completed in December 1999
and included 27 European and North American transplant cen-
ters. Fifty-nine patients who ranged in age from 3.3 to 15.9
(median, 10.1) years received HLA-identical sibling marrow allo-
grafts between September 1991 and April 2000. Indications for
BMT included stroke (N=31), recurrent episodes of acute chest
syndrome (N=20), and recurrent painful episodes (N=8). Patients
received a combination of cyclophosphamide, busulfan, and anti-
thymocyte globulin or CAMPATH antibody before transplanta-
tion. Most patients received a combination of CSP and
methotrexate to prevent GVHD. Fifty-ﬁve patients survive, and
51 survive free from SCD, with a median follow-up of 34.7
(range, 3.5 to 94.8) months after BMT. Four patients died of
GVHD (N=3) or intracranial hemorrhage (N=1) and 5 experi-
enced recurrent SCD. The Kaplan-Meier probabilities of survival
and event-free survival are 92% and 83%, respectively, and the
cumulative incidence of graft rejection is 9%. Although no single
factor achieved statistical significance for an association with
rejection, the odds ratio for rejection among patients receiving
iron chelation therapy was increased 7-fold, suggesting that
transfusion exposures increased the risk of rejection. Of interest,
5 patients developed stable mixed donor-host chimerism which
has persisted for 11.8-64.4 (median 24) months. Allograft recipi-
ents with stable mixed chimerism had HbS fractions similar to
donor levels and only one patient required a RBC transfusion
beyond 90 days after BMT. None of these patients experienced
painful events or other clinical complications related to sickle cell
disease after BMT, including those patients who had a minority
of donor cells. Taken together, these observations confirm that
conventional allogeneic BMT has curative potential for SCD. In
addition, the signiﬁcant beneﬁt experienced by those who devel-
oped persistent donor-host chimerism suggests that investiga-
tions of non-myeloablative BMT for genetic disorders like SCD
are well-founded.
